BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30170077)

  • 1. DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.
    Kawai M; Nakamura T; Miura N; Maeta M; Tanaka H; Ueda K; Higashi K; Moribe K; Tange K; Nakai Y; Yoshioka H; Harashima H; Akita H
    Nanomedicine; 2018 Nov; 14(8):2587-2597. PubMed ID: 30170077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma.
    Akita H; Ishiba R; Togashi R; Tange K; Nakai Y; Hatakeyama H; Harashima H
    J Control Release; 2015 Feb; 200():97-105. PubMed ID: 25543000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug.
    Togashi R; Tanaka H; Nakamura S; Yokota H; Tange K; Nakai Y; Yoshioka H; Harashima H; Akita H
    J Control Release; 2018 Jun; 279():262-270. PubMed ID: 29673647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin E Scaffolds of pH-Responsive Lipid Nanoparticles as DNA Vaccines in Cancer and Protozoan Infection.
    Maeta M; Miura N; Tanaka H; Nakamura T; Kawanishi R; Nishikawa Y; Asano K; Tanaka M; Tamagawa S; Nakai Y; Tange K; Yoshioka H; Harashima H; Akita H
    Mol Pharm; 2020 Apr; 17(4):1237-1247. PubMed ID: 32129629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine.
    Tateshita N; Miura N; Tanaka H; Masuda T; Ohtsuki S; Tange K; Nakai Y; Yoshioka H; Akita H
    J Control Release; 2019 Sep; 310():36-46. PubMed ID: 31386869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hydrophobic scaffold on the cellular uptake and gene transfection activities of DNA-encapsulating liposomal nanoparticles via intracerebroventricular administration.
    Akita H; Nakatani T; Kuroki K; Maenaka K; Tange K; Nakai Y; Harashima H
    Int J Pharm; 2015 Jul; 490(1-2):142-5. PubMed ID: 26003418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutral biodegradable lipid-envelope-type nanoparticle using vitamin A-Scaffold for nuclear targeting of plasmid DNA.
    Tanaka H; Akita H; Ishiba R; Tange K; Arai M; Kubo K; Harashima H
    Biomaterials; 2014 Feb; 35(5):1755-61. PubMed ID: 24290811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an SS-Cleavable pH-Activated Lipid-Like Material (ssPalm) as a Nucleic Acid Delivery Device.
    Akita H
    Biol Pharm Bull; 2020; 43(11):1617-1625. PubMed ID: 33132308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.
    Yuba E; Kanda Y; Yoshizaki Y; Teranishi R; Harada A; Sugiura K; Izawa T; Yamate J; Sakaguchi N; Koiwai K; Kono K
    Biomaterials; 2015 Oct; 67():214-24. PubMed ID: 26222284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment.
    Nakamura T; Kawakami K; Nomura M; Sato Y; Hyodo M; Hatakeyama H; Hayakawa Y; Harashima H
    J Control Release; 2022 May; 345():200-213. PubMed ID: 35307507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.
    Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
    Biomaterials; 2014 Sep; 35(28):8186-96. PubMed ID: 24969637
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Hasan T; Kawanishi R; Akita H; Nishikawa Y
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062682
    [No Abstract]   [Full Text] [Related]  

  • 17. A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant.
    Miura N; Shaheen SM; Akita H; Nakamura T; Harashima H
    Nucleic Acids Res; 2015 Feb; 43(3):1317-31. PubMed ID: 25605799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
    Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ
    Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy.
    Yuba E; Tajima N; Yoshizaki Y; Harada A; Hayashi H; Kono K
    Biomaterials; 2014 Mar; 35(9):3091-101. PubMed ID: 24406217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.